Canada approves GSK’s Arexvy vaccine for RSV protection in adults 50-59 at elevated risk

Canada approves GSK’s Arexvy vaccine for RSV protection in adults 50-59 at elevated risk

In a crucial development for public health, Health Canada has extended its approval for GlaxoSmithKline’s Arexvy vaccine to include adults aged 50 to 59 who face a heightened risk from respiratory syncytial virus (RSV) due to underlying health conditions. This expanded approval marks a significant move in Canada’s battle against RSV, a respiratory virus that, […]